Omada Health (NASDAQ:OMDA) CFO Steven Cook Sells 33,000 Shares of Stock

Omada Health, Inc. (NASDAQ:OMDA) CFO Steven Cook sold 33,000 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $19.89, for a total transaction of $656,370.00. Following the completion of the transaction, the chief financial officer owned 133,359 shares in the company, valued at approximately $2,652,510.51. The trade was a 19.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Omada Health Stock Performance

NASDAQ:OMDA opened at $21.95 on Wednesday. The firm has a market cap of $1.30 billion and a P/E ratio of -81.30. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92. The firm has a 50-day simple moving average of $16.83 and a two-hundred day simple moving average of $14.93.

Omada Health (NASDAQ:OMDA) last issued its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. The firm had revenue of $78.05 million for the quarter. On average, equities research analysts predict that Omada Health, Inc. will post -0.01 EPS for the current year.

Analyst Upgrades and Downgrades

OMDA has been the subject of several recent analyst reports. Wells Fargo & Company boosted their price target on Omada Health from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Evercore reiterated an “outperform” rating and issued a $20.00 price objective on shares of Omada Health in a report on Friday, May 8th. Weiss Ratings raised Omada Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. JPMorgan Chase & Co. lowered their target price on shares of Omada Health from $32.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, March 12th. Finally, Citizens Jmp lifted their price target on shares of Omada Health from $18.00 to $21.00 and gave the stock a “market outperform” rating in a research note on Friday, May 8th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $22.91.

Institutional Trading of Omada Health

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC purchased a new position in Omada Health in the second quarter worth about $637,000. Walleye Capital LLC purchased a new stake in shares of Omada Health during the 2nd quarter valued at about $458,000. Ilex Capital Partners UK LLP purchased a new stake in shares of Omada Health during the 2nd quarter valued at about $201,000. Soros Fund Management LLC bought a new position in shares of Omada Health in the 2nd quarter worth approximately $640,000. Finally, Raymond James Financial Inc. bought a new position in shares of Omada Health in the 2nd quarter worth approximately $32,000.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.